Exelixis, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Morrissey
- Full Time Employees
- 1,077
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1851 Harbor Bay Parkway Alameda CA United States of America 94502
- IPO Date
- Apr 17, 2000
- CIK
- 0000939767
- Website
- exelixis.com
- Similar Companies
- Business
- Exelixis, Inc. (Nasdaq: EXEL) is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers. The company offers CABOMETYX (cabozantinib) tablets for advanced renal cell carcinoma, hepatocellular carcinoma, and previously treated advanced neuroendocrine tumors; COMETRIQ (cabozantinib) capsules for metastatic medullary thyroid cancer; and COTELLIC (cobimetinib), partnered with Roche/Genentech for advanced melanoma. Exelixis advances a diversified pipeline of small-molecule therapeutics and biotherapeutics, including bispecific antibodies, antibody-drug conjugates, next-generation kinase inhibitors such as zanzalintinib in phase 3 trials for renal cell carcinoma, hepatocellular carcinoma, and squamous cell carcinoma of the head and neck, and early-stage programs like XL309 targeting PARP inhibitors. Founded in 1994 and headquartered in Alameda, California, the company conducts global operations through strategic partnerships with Bristol Myers Squibb, Merck, Takeda Pharmaceutical, and others to expand development and commercialization reach. Recent developments include U.S. FDA approval of a new CABOMETYX indication for previously treated advanced neuroendocrine tumors; authorization of a $500 million stock repurchase program in February 2025 following completion of a prior $500 million program from August 2024, with over $1.2 billion returned to shareholders since March 2023; plans to initiate phase 3 trials for zanzalintinib in neuroendocrine tumors and two Merck-collaborated renal cell carcinoma studies in 2025; and ongoing enrollment in XL309 monotherapy and combination trials for PARP-refractory tumors.
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
Allspring Global Investments Holdings LLC Acquires 323,895 Shares of Exelixis, Inc. $EXEL
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
3 Under-the-Radar Stocks to Buy and Hold
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?
Stocks Look Shaky, But This Sector is Booming (Biotech)
Here's Why Exelixis (EXEL) is a Strong Growth Stock
EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
Here's Why Exelixis (EXEL) is a Strong Value Stock
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Exelixis Hits High on Growing Sales, Institutional Inflows
Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript